Learn how ClaimGuardRx addresses both diversion and fraud through a single, conversational platform. Understand why the voice ...
Caspian Therapeutics was launched with $50 million to progress KO-7246 through IND-enabling development and early clinical evaluation in patients with diabetes. Menin inhibition is positioned as ...
Recognize the role human factors expertise, onboarding, and training and education play in building patient confidence and supporting long-term adherence. Joe Reynolds, Head of User Experience ...
When a drug already sold at a steep 340B discount generates another rebate request, how can manufacturers determine whether ...
Recognize what makes ClaimGuardRx's proprietary, domain-specific LLM different from repurposed fraud tools. Understand how the platform's detect-and-respond design shortens the time between spotting a ...
An oversubscribed $70 million Series B, co-led by Alpha Wave and YK Bioventures with Eli Lilly participation, funds clinical ...
Aptar Pharma and Aceso Therapeutics team up to advance an inhaled cystic fibrosis therapy, Moonwalk Biosciences raises a $70 ...
Our survey findings highlight the critical need for reforms to ensure that IBD patients can access the medications they need ...
Sebastian Arana, head of process solutions at MilliporeSigma, discusses the operational tradeoffs facilities face as they ...
Carelon Research's Mark Cziraky on why analyzing RWD in place — rather than licensing it out — is reshaping how evidence gets ...
Model N's Jesse Mendelsohn examines the growing stakes surrounding the 340B Drug Pricing Program — and how claims data, rebate models and simmering legal challenges are influencing manufacturer ...
FDA approved zilganersen as the first disease-modifying therapy for Alexander disease, an ultra-rare, progressive ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results